Prudential Financial Inc. lessened its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 26.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,255 shares of the medical instruments supplier’s stock after selling 30,034 shares during the period. Prudential Financial Inc. owned approximately 0.19% of STAAR Surgical worth $2,720,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in STAA. First Quadrant L P CA bought a new position in shares of STAAR Surgical during the 4th quarter valued at about $92,000. Bank of Montreal Can lifted its holdings in shares of STAAR Surgical by 903.3% during the 4th quarter. Bank of Montreal Can now owns 3,050 shares of the medical instruments supplier’s stock valued at $97,000 after purchasing an additional 2,746 shares in the last quarter. Xact Kapitalforvaltning AB lifted its holdings in shares of STAAR Surgical by 31.0% during the 4th quarter. Xact Kapitalforvaltning AB now owns 7,600 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 1,800 shares in the last quarter. United Services Automobile Association bought a new position in shares of STAAR Surgical during the 3rd quarter valued at about $278,000. Finally, Advisors Asset Management Inc. bought a new position in shares of STAAR Surgical during the 3rd quarter valued at about $302,000. Institutional investors and hedge funds own 90.06% of the company’s stock.
Several research firms have recently weighed in on STAA. BidaskClub cut STAAR Surgical from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 20th. TheStreet cut STAAR Surgical from a “b-” rating to a “c” rating in a research note on Friday, December 14th. ValuEngine cut STAAR Surgical from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 21st. Finally, Zacks Investment Research cut STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, March 2nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $45.25.
NASDAQ STAA opened at $36.58 on Friday. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of 130.64 and a beta of 2.11. STAAR Surgical has a 52 week low of $13.60 and a 52 week high of $54.00.
STAAR Surgical (NASDAQ:STAA) last released its earnings results on Thursday, February 21st. The medical instruments supplier reported $0.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.01. The firm had revenue of $31.19 million for the quarter, compared to analysts’ expectations of $31.20 million. STAAR Surgical had a return on equity of 13.86% and a net margin of 4.01%. On average, equities research analysts expect that STAAR Surgical will post 0.3 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2019/03/17/staar-surgical-staa-stake-decreased-by-prudential-financial-inc.html.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
See Also: What is the Coverage Ratio?
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.